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1Department of Internal Medicine, Division of Kidney Diseases and Hypertension, Hofstra Northwell School of Medicine,
Northwell Health, Great Neck, New York, USANovel targeted anti-cancer therapies have resulted in improvement in patient survival compared to
standard chemotherapy. Renal toxicities of targeted agents are increasingly being recognized. The inci-
dence, severity, and pattern of renal toxicities may vary according to the respective target of the drug. Here
we review the adverse renal effects associated with a selection of currently approved targeted cancer
therapies, directed to EGFR, HER2, BRAF, MEK, ALK, PD1/PDL1, CTLA-4, and novel agents targeted to
VEGF/R and TKIs. In summary, electrolyte disorders, renal impairment and hypertension are the most
commonly reported events. Of the novel targeted agents, ipilumumab and cetuximab have the most
nephrotoxic events reported. The early diagnosis and prompt recognition of these renal adverse events
are essential for the general nephrologist taking care of these patients.
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).I n the past decade, advances in cell biology have ledto development of anticancer agents that target
speciﬁc molecular pathways. The National Cancer
Institute (NCI) deﬁnes targeted therapies as “drugs or
substances that block the growth and spread of cancer
by interfering with speciﬁc molecules involved in
tumor growth and progression.”1 Targeted therapies
are commonly used in cancer treatment, and it is vital
that their renal toxicities be recognized and investi-
gated. Adverse renal effects of targeted therapies
occur through several complex mechanisms. Wide
ranges of toxicities affecting various parts of the
nephron have been reported with the novel targeted
therapies. Recognition of adverse renal effects of these
agents in a timely manner is extremely important for
optimal patient care. Table 1 summarizes the onco-
logical indications for the major targeted therapies
discussed in this review. Figure 1 summarizes the
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FDA ADVERSE REPORTING SYSTEM REVIEW
A recent study by our group had reviewed the Food
and Drug Administration (FDA) Adverse Event
Reporting System (FAERS) data from 2011 to 2015 and
found a high number of renal adverse events with
novel targeted therapies.2 The total number of renal
adverse events reported was 2943. Of the 3 categories
of events, 1390 (47.3%) were metabolic disturbances,
1243 (42.2%) were renal impairment, and 310 (10.5%)
were hypertension (HTN). Ipilumumab and cetuximab,
with 508 and 467 events respectively, were the most
common targeted therapies associated with reported
nephrotoxicities. The rate of adverse events were
similar between men (n ¼ 1369) and women (n ¼
1305).2 Renal impairment was reported in 636 men
and 522 women (P < 0.001). Metabolic disturbances
were reported in 620 men and 639 women (P ¼ 0.5).
HTN was reported with 113 men and 144 women
(P ¼ 0.053).2 The most common electrolyte abnormality
was hypokalemia (n ¼ 539). This analysis indicates that
electrolyte abnormalities are the most common renal or
metabolic toxicity. Overall, for all renal events, there
was no difference in the incidence between men and
women. However, men seem to have a higher risk ofKidney International Reports (2017) 2, 108–123
Table 1. Approved hematology and oncology indications for targeted therapies along with dosing in CKD and ESRD
Generic name of targeted
therapy (trade name) Target Cancer Renal excretion
Dose adjustment for
GFR 30--90 ml/min/1.73 m2
Dialysis dose
adjustment
Afatineb (Gilotrif) EGFR TKI Metastatic NSCLC <5% No No data
Axitinib (Inlyta) Multi target TKI Pancreatic cancer, RCC, CML <25% No No
Aﬂibercept (Eylea or Zaltrap) VEGF Colorectal cancer No No No
Bevacizumab (Avastin) VEGF Colorectal cancer, NSCLC, RCC, breast cancer,
epithelial ovarian cancer, GBM
No No No
Bosutinib (Bosulif) BCR-ABL TKI CML No Reduce dose to 300 mg once daily No data
Cetuximab (Erbitux) EGFR Colorectal cancer, head and neck SCC No No No
Crizotinib (Xalkori) ALK NSCLC No No No
Dabrafenib (Taﬁnlar) BRAF Melanoma <25% No No data
Dasatinib (Sprycel) BCR-ABL TKI CML <5% No No data
Erlotinib (Tarceva) EGFR TKI NSCLC, pancreatic cancer <10% No No
Geﬁtinib (Iressa) EGFR TKI NSCLC <5% No No
Ibrutinib (Imbruvica) Bruton kinase TKI CLL, mantle cell lymphoma No No data No data
Imatinib (Gleevac) BCR-ABL TKI Gastrointestinal stromal tumors, CML <15% No No
Ipilimumab (Yervoy) CTLA4 Melanoma No No No data
Lapatinib (Tykerb) ERBB2 Breast cancer <5% No No
Nivolumab (Opdivo) PD-1 Melanoma, NSCLC, Hodgkin lymphoma, RCC No No No data
Nilotinib (Tasigna) BCR-ABL TKI CML No No No data
Panitumumab (Vectibix) EGFR Colorectal cancer No No No
Pazopanib (Votrient) Multitarget TKI RCC, soft tissue sarcoma <4% No No
Pembrolizumab (Keytruda) PD-L1 Melanoma, NSCLC, Hodgkin lymphoma No data No No
Pertuzumab (Perjeta) ERBB2 Breast cancer No No No data
Ponatanib (Iclusig) BCR-ABL TKI CML, ALL No No No data
Regorafenib (Stivarga) Multitarget TKI Colorectal cancer, gastrointestinal stromal tumors <20% No No
Sorafenib (Nexavar) Multitarget TKI RCC, hepatocellular carcinoma, thyroid carcinoma <20% No No
Sunitinib (Sutent) Multitarget TKI RCC, gastrointestinal stromal tumors,
pancreatic neuroendocrine tumors
<20% No No
Trametinib (Mekinist) MEK Melanoma <20% No No data
Trastuzumab (Herceptin) ERBB2 Breast cancer No No No
Vandetanib (Caprelsa) Multitarget TKI Medullary thyroid cancer <25% No No data
Vemurafenib (Zelboraf) BRAF Melanoma, thyroid cancer, colorectal cancer <5% No No data
ALK, anaplastic lymphoma kinase; ALL, acute lymphocytic leukemia; BCR-ABL, breakpoint cluster region–abelson; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous
leukemia; CTLA, cytotoxic T lymphocyte antigen4; EGFR, epidermal growth factor receptor; GBM, gliobastoma multiforme; MEK, mitogen-activated protein kinase; NSCLC, nonsmall-
cell lung cancer; PD, programmed cell death; RCC, renal cell carcinoma; SCC, squamous cell cancer; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor.
Information obtained from package inserts of agents, clinical trials, and published case reports.
No data available for most agents for dose adjustments for GFR < 30 ml/min/1.73 m2 except vandetanib, which requires dose adjustment.
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compared to women. No such gender difference exists
in standard chemotherapy-related acute kidney injury
(AKI). There was no difference in gender for electrolyte
disorders and HTN associated with targeted therapies.2
Hypokalemia, hypophosphatemia, hypomagnesemia,
and hyponatremia are concerns in patients receiving
targeted therapies.
There are important limitations that one must keep
in mind when using the FAERS database. The events
are reported by providers and/or patients and therefore
could have a reporting bias. In addition, not all de-
mographic and comorbidity information is available to
help identify whether other nephrotoxic risk factors
are present, such as use of nonsteroidal anti-
inﬂammatory agents, history of HTN or diabetes mel-
litus, known chronic kidney disease (CKD), recent use
of contrast agent, or recent use of standard chemo-
therapy that could be nephrotoxic. Most importantly,
it is not possible to determine whether an event is trulyKidney International Reports (2017) 2, 108–123caused by the drug as opposed to the underlying dis-
ease or concomitant medications or by prior chemo-
therapies administered to these patients. In addition,
we cannot get an accurate assessment of incidence rate,
as we do not have complete information on the total
number of patients who have actually received these
agents.
In this narrative review, we discuss the renal
adverse events of a few novel antivascular endothe-
lial growth factor (VEGF) and tyrosine kinase inhibitors
(TKI) but focus more on the other novel targeted
therapies used in cancer patients. We also compare the
published renal adverse data to the FDA-reported
events, providing a comprehensive overview on the
toxicities.
VEGF AND VEGF RECEPTOR BLOCKADE
A hypothesis that tumor growth is angiogenesis depen-
dent led to the development of antiangiogenic drugs.3
These drugs target the VEGF or VEGF receptor109
Figure 1. Summary of renal adverse events noted with targeted therapies. ALK, anaplastic lymphoma kinase; BCR-ABL, breakpoint cluster
region–abelson; CTLA, cytotoxic T lymphocyte antigen4; EGFR, epidermal growth factor receptor; HER-2, human epidermal growth factor2;
PD, programmed cell death; TKI, tyrosine kinase inhibitors; VEGF, vascular endothelial growth factor.
REVIEW KD Jhaveri et al.: Adverse Renal Effects of Oncologic Targeted Therapies(VEGFR). The VEGF ligand inhibitors (bevacizumab
and aﬂibercept) bind to the VEGF molecule, preventing
it frombinding to the receptor and inhibiting endothelial
cell proliferation and vessel formation. Bevacizumab and
aﬂibercept can produce asymptomatic albuminuria,
nephrotic syndrome, and thrombotic microangiopathy
(TMA).4 Eremina et al. showed that podocyte-speciﬁc
knockout of the VEGF gene resulted in renal limited
TMA.5 Most drugs that target the VEGF pathway can
present with 1 of the known renal toxicities. HTN
frequently accompanies proteinuria. Although protein-
uria appears to be an effect common to all agents targeted
at the VEGF pathway, the factors associated with the
occurrence and severity of the proteinuria are un-
known.4 Pre-existing renal disease (including higher
baseline urinary protein levels and hypertension) and
renal cell carcinoma (as compared to other malignant
diseases) may be predisposing factors.4 Table 2 summa-
rizes the known renal toxicities of VEGF-inhibitory
agents. The HTN associated with anti-VEGF
agents is mediated via several mechanisms. Decreased
nitrous oxide leading to endothelial dysfunction and
capillary rarefaction, pressure natriuresis, and decreased
lymph-angiogenesis leading to volume overload are
proposed mechanisms that cause the HTN,6 but some-
times additional classes of agents are required for man-
agement. Choice of antihypertensive agents should be110individualized, with angiotensin-converting enzyme
inhibitor (ACEI) or angiotensive receptor blocker (ARB)
inhibition as ﬁrst-line options and calcium channel
blockers as a reasonable second choice. Centrally acting
antihypertensive or diuretic agents may be added to
adequately control blood pressure. Close follow-up is
critical for appropriate titration, and if the blood pres-
sure cannot be maintained below 140/90 mm Hg (or 130/
89 mm Hg in certain high-risk groups), then prompt
referral to a hypertension specialist is indicated. If pa-
tients develop hypertensive crisis or encephalopathy,
the cancer therapy needs to be discontinued. The pro-
teinuria associated with these agents is due to disruption
of the glomerular ﬁltration barrier.7,8 A kidney biopsy
sample usually shows renal limited TMA and in some
cases minimal change disease (MCD) or focal segmental
glomerulosclerosis (FSGS).9 Treatment can be continued
in most cases involving nonnephrotic-range protein-
uria, and HTN and proteinuria can be aggressively
managed with ACEIs or ARBs. Since treatment
options and prognosis might be inﬂuenced by kidney
histological ﬁndings, a kidney biopsy is usually recom-
mended whenever feasible. The decision to stop
anti-VEGF therapy or to switch to alternative agents
shouldbemade in the setting of signiﬁcant proteinuria in
a multidisciplinary setting. Nephrotic-range protein-
uria and TMA are generally considered reasons toKidney International Reports (2017) 2, 108–123
Table 2. Tyrosine kinase inhibitors and VEGF inhibitory
drugrelated renal toxicities
Agent Reported nephrotoxicity References
VEGF/R antibodies
Bevacizumab HTN, proteinuria, preeclampsia-like
syndrome, renal limited TMA
4–10
Aﬂibercept HTN, proteinuria 4–10
Receptor TKIs, VEGF family
Sunitinib HTN, proteinuria, MCD/FSGS, AIN,
chronic interstitial nephritis
7, 9, 13
Pazopanib HTN, proteinuria 7, 9
Axitinib HTN, proteinuria 7, 9
Sorafenib HTN, proteinuria, MCD/FSGS, AIN, chronic
interstitial nephritis, hypophosphatemia
7, 9, 13, 14
Regorafenib HTN, hypophosphatemia,
hypocalcemia, proteinuria, AKI
2, 17, 18
Vandetanib HTN, hypokalemia, hypocalcemia 2, 19
Cellular TKIs, BCR-ABL
Imatinib ATN, Rhabdomyolysis,
hypophosphatemia
2, 26–29, 32–34
Nilotinib HTN 7, 9, 37
Ponatinib HTN 7, 9
Dasatinib Rhabdomyolysis, ATN, proteinuria, TMA 40–46
Bosutinib Hypophosphatemia 47
AIN, acute interstitial nephritis; AKI, acute kidney injury; FSGS, focal segmental
glomerulosclerosis; HTN, hypertension; MCD, minimal change disease; TKI, tyrosine
kinase inhibitor; TMA, thrombotic microangiopathy; VEGF, vascular endothelial growth
factor; VEGF/R, vascular endothelial growth factor/receptor.
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views on anti-VEGF agents that induced kidney dis-
ease4,10 exist in the literature, and this review will not
focus on those agents.
TYROSINE KINASE INHIBITORS
An important mechanism in signal transduction
pathways in cells is protein phosphorylation, which is
carried out by protein kinases. These kinases regulate
the proliferation, differentiation, migration, meta-
bolism, and antiapoptotic signaling of cells. The most
important kinases are the serine/threonine and tyro-
sine kinases, which are characterized by their ability
to catalyze the phosphorylation of serine/threonine or
tyrosine amino acid residues in proteins respectively.
There are 2 types of tyrosine kinases: cellular and
receptor tyrosine kinases.11 Imatinib is a cellular
tyrosine kinase inhibitor (TKI) that is designed to
target the fusion protein breakpoint cluster region–
abelson (BCR-ABL) and members of the SRC tyrosine
kinase family. Receptor TKIs are designed to target the
epidermal growth factor (EGFR), platelet-derived
growth factor (PDGFR), and the VEGFR tyrosine ki-
nase families. These could target single receptors such
as EGFR (geﬁtinib) or could be multikinase or
multitarget TKIs and target many receptors such as
sunitinib, which targets VEGFR,1–3 PDGFR, kit, Flt3
and RET.11 Figure 2 is a simpliﬁed version of the
different types of TKIs used in cancer treatment.Kidney International Reports (2017) 2, 108–123Receptor TKIs: TKIs of the PDGFR Family
PDGFR inhibitors are in clinical development for
cancer therapy; most are directed against several
tyrosine kinases. Examples of these agents are les-
taurtinib and tandutinib, which are used for treatment
of leukemia and pancreatic cancer, respectively. Since
they are in phase I and II trials, they will not be
discussed here.12
Receptor TKIs: TKIs of the VEGFR Family
Sunitinib and sorafenib inhibit angiogenesis and cell
proliferation by targeting multiple receptor kinases,
including VEGFRs, PDGFRs, c-KIT, and others.13
Similar to anti-VEGF agents, these agents are potent
inhibitors of angiogenesis and lead to adverse effects
similar to them. TKIs (sunitinib, sorafenib, pazopanib,
axitinib, cabozantinib, lenvatinib, and vandetanib)
block the intracellular domain of the VEGFR. Sunitinib,
sorafenib, pazopanib, and axitinib have known effects
of HTN, proteinuria, TMA, and chronic, and acute
interstitial nephritis.4,13 Sorafenib also is known to
cause hypophosphatemia and hypocalcemia. This effect
has been linked to pancreatic dysfunction from the
drug, leading to vitamin D malabsorption and sec-
ondary hyperparathyroidism.14 Hence, patients on this
agent should be screened for vitamin D, phosphorous,
and calcium levels. Since the advent of antiangiogenic
agents, newer agents with other molecular targets1
have been approved. The renal toxicities VEGFR-
related TKIs are well described in the nephrology and
oncology literature and are not discussed in further
detail in this review; however, the renal toxicities of
the newer targeted therapies are limited to case reports
or series. In this review, we discuss 2 novel VEGF-
receptorbased TKI agents with emerging data,
namely, regorafenib and vandetanib.
Regorafenib
Regorafenib is associated with several electrolyte ab-
normalities, including hypophosphatemia, hypocalce-
mia, hyponatremia, and hypokalemia.2,15,16 These
abnormalities are usually mild to moderate and do not
require dose reductions or treatment interruptions.
Initial trials reported the incidence of HTN to be
around 28%, of which 7% were listed as grade 3.15 The
incidence of proteinuria was lower at 7%, and 1%
were grade 3.15 A recent trial found HTN in 11% of
patients and hypophosphataemia in 7% of patients.16
According to Yilmaz et al., the HTN associated with
regorafenib may not be a dose-dependent effect.17 A
systematic review by Wang et al. evaluated 1069 pa-
tients (regorafenib, n¼ 750; controls, n¼ 319) from 5
clinical trials. The overall incidence of all-grade HTN
was 44.4% (95% conﬁdence interval [CI] 30.8%–
59.0%).18 The use of regorafenib in cancer patients was111
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Figure 2. Simplistic view of various tyrosine kinases available for treatment of cancer. There are 2 types of tyrosine kinases: cellular and
receptor tyrosine kinases. Receptor tyrosine kinase inhibitors (TKIs) are designed to target the epidermal growth factor (EGFR), platelet-derived
growth factor (PDGFR), and vascular endothelial growth factor receptor (VEGFR) tyrosine kinase families. These could target single receptors
such as EGFR (geﬁtinib) or could be multikinase or multitarget TKIs and target many receptors such as sunitinib, which targets VEGFR,1–3
PDGFR, kit, Flt3, and RET. The figure represents the predominant receptor involved as the target.
REVIEW KD Jhaveri et al.: Adverse Renal Effects of Oncologic Targeted Therapiesassociated with a signiﬁcantly increased risk of all-
grade HTN (relative risk [RR] ¼ 3.76, 95% CI ¼
2.35–5.99).18 Our analysis of FAERS data found 125
cases of regorafenib-related renal toxicity. Similar to
the published literature, HTN was the most common
adverse event (57 cases), followed by AKI (40 cases) and
hypophosphatemia (8 cases). It is interesting that AKI
has not been described in prior studies with this
agent.2 Given the lack of published biopsy-proven
cases, pathophysiology is not easy to elicit in
regorafenib-induced AKI. The mechanism of hypo-
phosphatemia might be similar to that of sorafenib, as
discussed above.
Vandetanib
Vandetanib is a receptor TKI that inhibits many tar-
gets including VEGFR2, EGFR, and RET. According to
initial studies, it has been associated with a number of
electrolyte disturbances, such as hypocalcemia, hy-
pokalemia, hyponatremia, and hypercalcemia.19,20
HTN has also been reported in close to 10% of
patients.19,21 Data from a phase 2 trial of vandetanib in
locally advanced or metastatic differentiated thyroid
cancer conﬁrmed that HTN is frequently seen in
nearly 34% of cases.22 Electrolyte disturbances,
namely hypokalemia and hypocalcemia, were seen at a
lower rate (4%).20 Vandetanib also been shown to
have an inhibitory activity on several human renal
transporters, such as MATE-1 and MATE-2, which are
responsible for the clearance of multiple drugs and
toxins. Inhibition of MATE-1 and MATE-223 at the112apical membrane of the tubular cells might lead to
increased concentrations of the drug within renal
cells, resulting in worsening of renal toxic effects of
other drugs; especially cisplatin.24 Despite this, a
Medline search did not reveal any published case re-
ports or series of any speciﬁc postmarketing renal
adverse events. In the FAERS analysis, a total of 57
cases were found, with a majority of AKI (30 cases),
followed by HTN (21 cases), and the remainder elec-
trolyte disorders.2
TKIs of the EGFR Family
Afatinib, erlotinib, and geﬁtinib are small-molecule
inhibitors of the tyrosine kinase domain of the EGFR,
which are used in the treatment of nonsmall-cell lung
cancer. Monoclonal antibodies targeting the EGFR
(cetuximab, panitumumab) are also used as targeted
therapies. Given their widely known association with
electrolyte disorders, both variants of EGFR inhibitors
are discussed below in a different section.
Cellular TKIs
Imatinib
Imatinib is a potent inhibitor of BCR-ABL fusion protein,
and platelet-derived growth factors. It is a TKI that is
classically used in chronic myelogenous leukemia (CML)
and gastric stromal tumors. In 1 study of patients with
CML, AKI was seen in 7% of patients and CKD in 12%.25
Potential mechanisms of injury appear to be tumor lysis
syndrome, biopsy-proven acute tubular damage, and or
Fanconi syndrome.26–30 Renal injury appears to be doseKidney International Reports (2017) 2, 108–123
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which higher doses are associated with higher incidence
of tubular damage. Interestingly, rhabdomyolysis has
been reported with this agent.32,33
A common electrolyte abnormality reported with
imatinib is hypophosphatemia. In 1 case series,
hypophosphatemia was associated with low calcium
and 25-OH vitamin D levels,34 with an incidence close
to 10%. This may be related to inhibition of renal
tubular reabsorption of phosphorus.35 The mechanism
underlying phosphaturia is unclear. The FAERS
report2 found 44 cases of imatinib-related renal
toxicity, and 25 events were AKIs, in line with pub-
lished literature. We found only 1 reported case of
hypophosphatemia reported to the FDA. In addition,
there were 5 cases of HTN, 3 of hypokalemia, and 4 of
hyponatremia that are not described in the literature.
Interestingly, based on rat models, imatinib may have
renal-protective effects. Reduced expression of trans-
forming growth factorb1 (TGF-b1) in the renal cor-
tex leads to suppression of proteinuria, improved
renal function, attenuation of glomerulosclerosis and
tubule-interstitial injury.36
Nilotinib
Nilotinib is an inhibitor of BCR-ABL kinase, c-KIT, and
PDGFR. It has been associated with HTN in 10% of
cases.37 Interestingly, in animal studies, nilotinib
signiﬁcantly decreased renal cortical expression of
proﬁbrogenic genes, such as IL-1b and monocyte
chemotactic protein1, which correlated closely with
tubulointerstitial damage; in addition, nilotinib treat-
ment signiﬁcantly prolonged survival of the rats.38
Ponatinib
Ponatinib is a BCR-ABL TKI, along with other targets
such as PDGFR, SRC kinases, and VEGFR. Given its
activity on VEGFR, the toxicities of anti-VEGF agents
can be applied to this agent. HTN might be common
ﬁnding with this agent.
Dasatinib
Dasatinib is a second-generation TKI used in imatinib-
resistant CML.39 It has effects on the BCR-ABL target
and other targets such as the PDGFR and c-KIT. There
are 3 published case reports of AKI with this drug.40–42
One case report of TMA43 and 1 case report causing
rhabdomyolysis44 similar to that with imatinib have
been reported. A possible mechanism of action could be
direct tubular toxicity, as noted in 1 of the published
cases with a kidney biopsy.40
There is a 5% incidence of proteinuria with this
agent.39 A case of biopsy-proven renal limited TMA
and another case with clinical TMA has been reported
with this agent.45,46 A possible mechanism for this
injury is through inhibition of the Src family kinasesKidney International Reports (2017) 2, 108–123that are required for VEGF signaling. It is possible that
the kidney injury could be similar to that with other
VEGF inhibitors. Of the TKIs that affect the BCR-ABL
pathway, this is the only agent associated with pro-
teinuric disease. Switching to imatinib or nilotinib
might be optimal for patients who develop proteinuria
on dasatinib.
Bosutinib
Bosutinib is a TKI approved for treatment of refractory
CML. Hypophosphatemia and a decline in GFR have
been reported during therapy with bosutinib.47 No
cases of renal toxicities with this agent have been
reported in the literature.
Other TKIs
Ibrutinib
Ibrutinib is a TKI that irreversibly binds to and inhibits
the Bruton tyrosine kinase. It is currently approved for
the treatment of chronic lymphocytic leukemia (CLL)
and mantle cell lymphoma. In 1 study, 23% of patients
developed elevated serum creatinine and edema.48 Of the
patients, 18% developed HTN as well.48 In another
study of patients with mantle cell leukemia, 35% had
increases in serum creatinine frombaseline. Therewere 4
cases of grade 3 AKI, but all were confounded by pre-
existing HTN and renal dysfunction, and concurrent
dehydration as well.49 Four patients also developed tu-
mor lysis syndrome, leading to electrolyte abnormalities
and AKI in this study.49 Patients receiving ibrutinib
should undergo periodic creatinine level monitoring and
should maintain hydration.49 The mechanism of this
injury is unclear at this point, but tumor lysis syndrome
could be a possible mechanism. No biopsy-proven cases
have been reported in the literature. In unpublished data
on cardiac effects of ibrutinib, 23% of the patients
developed new-onset systolic HTN with increases in
systolic blood pressure >20 mm Hg. The mechanism of
the HTN is also unclear.
EPIDERMAL GROWTH FACTOR RECEPTORL1
TARGET INHIBITORS
These therapies target the epidermal growth factor
receptor1 (EGFR). They include 2 monoclonal anti-
bodies, namely, cetuximab and panitumumab. Other
EGFR therapies include 3 small-molecule TKI, namely,
erlotinib, geﬁtinib, and afatinib. Table 3 summarizes
data reported in the literature and prior clinical trials
investigating these 5 agents.
Cetuximab
This monoclonal antibody against EGFR 1 is known to
cause hypomagnesemia.50 This happens as a result of
reduction in the transport of transient receptor poten-
tial melastatin (TRPM) 6/7 ion channels to the apical113
Table 3. Summary of renal toxic events with EGFR targeting agents
Drug Renal adverse events reported References
Cetuximab
(monoclonal antibody)
Hypomagnesaemia, hypokalemia,
AKI, hyponatremia, glomerulonephritis
2, 52–58
Panitumumab
(monoclonal antibody)
Hypomagnesaemia, AKI, hypokalemia 2, 53, 65, 66
Erlotinib (anti-EGFR TKI) AKI, hypomagnesemia, hypophosphatemia 2, 53, 68, 69
Afatinib (anti-EGFR TKI) AKI, hypokalemia, hyponatremia 2, 53
Geﬁtinib (anti-EGFR TKI) AKI, hypokalemia, ﬂuid retention,
minimal change disease, proteinuria
2, 53, 72–74
AKI, acute kidney injury; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase
inhibitor.
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nesium (Mg) is reabsorbed mainly in the thick
ascending limb of Henle and the distal tubule, where
most of the EGFR is located in the kidney. Epidermal
growth factor is an autocrine paracrine hormone that
regulates renal Mg reabsorption by regulating the
activity and transport of TRPM6.51 Blocking EGFR
with cetuximab blunts the movement of TRPM6/7
channel, which leads to renal Mg wasting and hypo-
magnesemia. The main risk factors for developing
hypomagnesemia are duration of treatment, age, and
baseline Mg values.52 Low Mg levels may lead to hy-
pokalemia, hypocalcemia, and cardiac arrhythmias.53
The literature review revealed multiple studies that
have reported hypomagnesemia as an adverse effect of
this agent.54,55 Severe grade 3 (<0.9–0.7 mg/dl) or 4
(<0.7 mg/dl, <0.3 mmol/l, life-threatening conse-
quences) hypomagnesemia has been seen in 36% and
27% of patients treated with cetuximab.56 Another
study showed the incidence of hypomagnesemia to be
close to 10% to 15%.30 A more recent study revealed
an incidence rate of hypomagnesemia with cetuximab
to be close to 30%. Of the cases, 22% were grade 1
(i.e., below the lower limit of normal to 1.2 mg/dl).57
There was no statistically signiﬁcant correlation
between Mg level and patient age, duration of treat-
ment, localization of primary tumor or metastases, and
number of metastases. However, there was an upward
trend in a logistic regression model showing that the
risk of developing hypomagnesemia increases with
age.57 Management of EGFR inhibitorinduced hypo-
magnesemia is summarized by Fakih in a review.58 One
has to ensure that the patient is not on any other
offending medication, such as thiazide diuretics or
proton pump inhibitors. For patients with grade 1 or 2
hypomagnesemia, oral Mg may be sufﬁcient after
discontinuation of cetuximab. Testing for Mg levels
should be performed every 2 to 3 weeks. For patients
who cannot tolerate oral Mg, i.v. Mg up to 4 g can be
given. Amiloride (Mg-sparing diuretic) has been tried in
unpublished case reports, with success in treating the
hypomagnsemia.59 For grades 3 and 4 hypomagnesemia,114patients should receive 6 to 10 g of magnesium sulfate
daily to twice weekly if possible. An initial strategy of
i.v. replacement and every other day monitoring of
magnesium levels can help guide frequency. An alter-
native strategy for patients requiring frequent
magnesium infusions may be to consider a 2-month
stop-and-go approach to cetuximab treatment.58
In our review of the literature, we also found 1 clinical
trial that reported renal failure in 2% of patients,60 1
published case report of a diffuse proliferative glomer-
ulonephritis,61 and another case report of nephrotic
syndrome.62 In our review of the FAERS, we found 467
individuals who had experienced renal events.2 This is
the second highest number of events for any of the tar-
geted therapies. Although the literature search revealed
hypomagnesaemia as the most commonly reported
toxicity,54,55 FAERS data suggest a high degree of renal
impairment with cetuximab.2 A total of 172 cases of AKI
with this agent were reported to FAERS.2 This was fol-
lowed by hypokalemia in 113 cases; hyponatremia, 78
cases; hypomagnesaemia, 58 cases; and HTN, 24 cases.
AKI might be an important ﬁnding that needs to be
studied further, as prior reviews do not discuss this in
detail.53 The cause of AKI is not reported in the FAERS
database. EGFR, which is mainly expressed in the distal
and collecting tubules, is involved in maintaining
tubular integrity. EGFR activation leads to growth and
generation of tubular epithelial cells after acute tubular
necrosis.63 In patients prone to experiencing renal
injury, treatment with anti-EGFR agents might be a
“second hit” for development of AKI.
Panitumumab
Panitumumab is a monoclonal antibody similar to
cetuximab. In the original trials, this agent was not
associated with any nephrotoxic effects.64 However, in
a recent phase 3 trial, for head and neck cancer, there
was a high incidence of hypomagnesemia (12%) and
hypokalemia (10%).65 Hypomagnesemia was reported
in 36% of patients who were treated with pan-
itumumab in a phase 3 trial for colorectal cancer.66 The
FAERS review found 337 renal adverse events with this
agent. The majority of the cases were of hypomagne-
semia (103 cases), followed by hypokalemia (85 cases)
and AKI (82 cases). Overall, there should be close Mg-
monitoring strategies in patients receiving EGFR
agents.67 Treatment strategies are similar to that for
cetuximab-induced hypomagnesemia.
Erlotinib
Compared to cetuximab and pantumumab, the next
few agents discussed here (erlotinib, geﬁtinib, and
afatinib) are TKIs that affect the EGFR. Erlotinib is a
small-molecule TKI that blocks the activity of theKidney International Reports (2017) 2, 108–123
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signaling pathways crucial for cancer cell survival.
Our literature search revealed no data on nephrotox-
icity with this agent. Erlotinib can inﬂuence magne-
sium handling, but its effect on the systemic
magnesium concentration seems less potent than that
observed with antibody-based EGFR inhibitors. Ani-
mal data suggest that typical human dosages of erlo-
tinib are unlikely to severely affect serum magnesium
concentrations.68 Although erlotinib can cause hypo-
magnesemia, the magnesium stearate supplementation
present as part of the erlotinib tablet might alleviate
the deﬁciency. Counter to data reported in the liter-
ature, our FAERS analysis found 63 cases of AKI and
only 8 cases of hypomagnesemia. Further research is
needed to clarify the association between erlotinib and
AKI.2 At this time, the mechanism of AKI is unclear.
The FAERS analysis also revealed 3 cases of hypo-
phosphatemia with erlotinib.2 A small phase 1 trial of
17 patients who used sorafenib and erlotinib for solid
tumors found a 76% incidence (13 of 17 patients) of
hypophosphatemia.69 A more recent, small phase 1 study
of 25 patients using erlotinib in gliomas found a 30%
incidence of hypophosphatemia.70 The mechanism of
erlotinib-induced hypophosphatemia is unclear, but
might involve sodium phosphate cotransporters in the
proximal tubule.53
Geﬁtinib
Similar to erlotinib, geﬁtinib is also a small-molecule TKI.
A literature review revealed ﬂuid retention in 6.6% of
patients.71 In addition, 1 case of AKI and another case of
nephrotic syndrome (due to an autoimmune response to
the agent) have also been reported.72,73 More recently, a
biopsy-proven case of MCDwas reported that responded
to drug withdrawal and a switch to erlotinib.74 Fifteen
cases of renal adverse events were noted in the FAERS
review,2 including 7 cases of AKI7, 4 cases of hypokale-
mia, and 2 cases of hyponatremia, but no cases of
hypomagnesemia.
Afatinib
In the initial trials of afatinib, there was a 34% inci-
dence of hypokalemia.75 No published cases of any
nephrotoxicities with this agent are reported in the
literature. In the FAERS, there were 26 cases of AKI,
followed by 6 cases of hypokalemia and 5 cases of
hyponatremia.2
HUMAN EPIDERMAL GROWTH FACTORL2
(HER-2) TARGET INHIBITORS
HER-2 is a membrane receptor that is overexpressed in
many forms of breast and gastric cancers. This receptor
is part of the EGFR family.Kidney International Reports (2017) 2, 108–123Trastuzumab
Trastuzumab is a recombinant humanized monoclonal
antibody that binds to the receptor tyrosine-kinase erbB-
2 (ERBB-2) on tumor cells and induces antibody-
mediated cellular toxicity in cells that overexpress this
protein. The drug alone does not cause renal toxicity, but
it can lead to cardiac toxicity and subsequently cardio-
renal syndrome.76 One study illustrated that GFR < 78
ml/min/1.73 m2 was the strongest predictor of cardiac
toxicity.76 In addition, in the TANDEM study, the
combination of trastuzumab and anastrozole was asso-
ciated with a higher incidence of HTN compared to
anastrozole alone.77 In the TOGA study, the arm that had
trastuzumab with standard chemotherapy had a higher
incidence of renal toxicity compared to the arm with
standard chemotherapy alone.78 More recently, a case of
tumor lysis syndrome has been reported with this
agent.79 In addition, there have now been a few cases of
fetal nephrotoxicity with renal impairment noted with
oligohydramnios and anhydramnios. In these cases,
there was spontaneous improvement of renal function in
the fetus after stopping traztuzumab.80–82 Additional
review of the literature found no published cases of
hypokalemia or hypomagnesemia, but there are 3 pub-
lished cases of hyponatremia. In each of the 3 cases, other
potentially hyponatremia-causing chemotherapies were
also involved.83–85 The FDA analysis indicated a large
number of cases reported of renal toxicity in the FAERS
database.2 Reports included 124 cases ofAKI, 112 cases of
hypokalemia, 52 cases of HTN, 24 cases of hypomagne-
semia, 28 cases of hyponatremia, and 11 cases of hypo-
phosphatemia.Most of the cases were females, as cancers
treated relate mainly to women.2 It is important to
monitor renal function, electrolytes, and blood pressure
in these patients, as AKI was reported to the FAERS
database in a number of cases. Given its known cardiac
toxicity, it is possible that the cases of AKI might be
related to a cardio-renal syndrome physiology and the
electrolyte disorders related to diuretic use.
Pertuzumab
Pertuzumab is a recombinant humanized monoclonal
antibody that targets the extracellular dimerization
domain of the ERBB-2. No published cases or reports of
renal toxicity are reported in the literature or from
clinical trials. Our FAERS analysis found a total of 100
cases; AKI (46 cases) and hypokalemia (26 cases) were
the top 2 causes.2
Lapatinib
Lapatinib is a dual tyrosine kinase inhibitor that in-
terrupts both the EGFR and ERBB-2 pathways. In a
phase 2 trial with this agent, 7 patients experienced
treatment-related grade 3 toxicity, and 2 of them115
Table 4. BRAF inhibitorrelated toxicity summary2,88-95,97,98
Allergic interstitial disease
Acute tubular necrosis
Proximal tubular damage (Fanconi syndrome)
Hypophosphatemia
Hyponatremia
Hypokalemia
Subnephrotic range proteinuria
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revealed no published reports of this agent leading to
AKI or any electrolyte disorders. Our analysis demon-
strated a total of 171 cases reported in the FAERS
database. Most cases were of hypokalemia (61 cases)
and AKI (48 cases). There were a few cases of HTN,
hypomagnesemia, and hyponatremia as well.2
BRAF TARGET INHIBITORS
Advanced melanoma has traditionally been unrespon-
sive to standard chemotherapy agents and formerly
had a dismal prognosis. Genetically targeted small-
molecule inhibitors of the oncogenic BRAF V600
mutation or a downstream signaling partner (mitogen-
activating protein kinase [MEK]) are effective treatment
options for the 40% to 50% of patients with melanoma
who harbor mutations in BRAF. Selective BRAF and
MEK inhibitors induce frequent and dramatic objective
responses and markedly improve survival compared
with cytotoxic chemotherapy.87–89 In the last decade
after discovery of this mutation, drugs such as
vemurafenib and dabrafenib have been approved by
the FDA and the European Medicines Agency for the
treatment of V-600 mutated melanomas. Although the
initial trials did not signal any renal toxicities with the
BRAF inhibitors, recent case reports, case series, and
the FDA adverse reporting systems have uncovered
signiﬁcant nephrotoxicities with these agents.87–89
Vemurafenib
In the initial phase III trial, 51 patients developed
edema, but there were no reports of proteinuria. There
were also no reported cases of AKI.87 In 2013, in a letter
to the editor, Uthurriague et al. were the ﬁrst to report
AKI. They reviewed 16 patients who were on this agent
for more than 8 months.88 Fifteen patients experienced
signiﬁcant decline in GFR at 1 month, with a mean
reduction of 29 ml/min, and this decline persisted for
3 months. Since then, multiple publications have
highlighted renal toxicities in various forms with this
agent, but mostly AKI and biopsy-proven ATN.89–94
Although biopsy-proven tubular toxicity93 has been
the mechanism of injury likely causing the AKI, a
recent study showed that vemurafenib induces a dual
mechanism of increase in plasma creatinine with both
an inhibition of creatinine tubular secretion and slight
renal function impairment. However, this adverse
effect is mostly reversible when vemurafenib is dis-
continued, and should not lead physicians to discon-
tinue the treatment if it is effective.95 Table 4
summarizes all known toxicities with this agent.
Our analysis of the FAERS database was reported
separately.94 In that publication, 132 cases of AKI were
reported in association with vemurafenib during the116timeframe reviewed. The toxicity was more common in
men.2,93,94
Dabrafenib
The European summary of product characteristics of
the drug reports that renal failure has been identiﬁed in
less than 1% of patients treated with dabrafenib.96
Recently, 1 case of biopsy-proven acute interstitial
nephritis was reported with this agent,97 which
responded to steroid treatment. The FDA data that we
analyzed were reported separately.94 Most of the cases
reported to the FAERS in that timeframe were AKI.94
Contrary to prior publications that had shown a 7%
incidence of hypophosphatemia,96 no cases of hypo-
phosphatemia were found in the FAERS database.94
Our group recently summarized the toxicities of the
BRAF agents, and that review provides more details.98
MITOGEN-ACTIVATED PROTEIN KINASE
ENZYMES MEK1 AND/OR MEK2 (MEK)
INHIBITORS
Trametinib
There have been no published cases of nephrotoxicity
with trametinib. Monotherapy with this agent can lead
to hypertension, but cases of AKI and hyponatremia
were noted more frequently in patients treated with
combined trametinib and dabrafenib.99 Our analysis
found similar results of a small number of cases of AKI
(28 cases) and hyponatremia (11 cases) with this agent.
Any renal toxicity may result from a combination ef-
fect with the BRAF inhibitors rather than a sole effect
of an MEK inhibitor.97
ANAPLASTIC LYMPHOMA KINASE (ALK)
TARGET INHIBITORS
Crizotinib
Crizitonib is an inhibitor of the anaplastic lymphoma ki-
nase (ALK) indicated in patientswith nonsmall-cell lung
cancer (NSCLC) who have ALK fusions. No renal adverse
events were reported in earlier clinical trials.100 However,
a recent study did report AKI in a patient treated with
this agent.101Abiopsy-proven case ofATNwas published
from France that was attributed to crizotinib.102
A recent analysis from the University of Colorado
looked at 38 patients with NSCLC who were treated
with this agent. The mean GFR decreased by 23.9%Kidney International Reports (2017) 2, 108–123
KD Jhaveri et al.: Adverse Renal Effects of Oncologic Targeted Therapies REVIEWcompared to baseline, and this was seen in the ﬁrst
2 weeks of therapy. Close to 84% of the patients
recovered renal function after cessation of therapy. The
investigators thought that the rapid reversibility raised
the possibility that the drug led to a defect in tubular
secretion of creatinine rather than a true drop in GFR.
The study did not report biopsy data.103 In addition,
renal cysts have been reported with crizotinib. The
cysts tend to be reversible and occur in 4% of pa-
tients.104,105 A series from Taiwan found changes in
renal cysts in 22% of patients who received this agent.
Crizotinib not only appears to be associated with for-
mation of new cysts but can also lead to progression of
prior existing cysts.106 The molecular mechanism by
which crizotinib increases risk of developing renal
cysts in currently unknown. In the FAERS analysis,2
consistent with the published reports, 88 cases of
renal impairment were noted. In addition, we found
evidence of electrolyte disorders as well (hyponatremia,
24 cases; hypokalemia, 13 cases). There is no evidence
of those disorders reported in the existing literature. In
summary, besides AKI, renal cyst formation and pro-
gression, hyponatremia and hypokalemia also need to
be considered with crizotinib. A recent review on this
topic summarizes the renal injury in depth.107
IMMUNE CHECKPOINT INHIBITOR:
PROGRAMMED CELL DEATHL1 AND LIGAND
TARGET (PD-1 AND PDL-1)
Cancer immunotherapy has revolutionized the treat-
ment of cancer by targeting the immune system rather
than the cancer. This pathway includes 2 proteins
called programmed death1 (PD-1), which is expressed
on the surface of immune cells, and programmed death
ligand1 (PD-L1), which is expressed on cancer cells.
The PD-1 molecule is expressed in activated T cells, B
cells, natural killer T cells, monocytes, and dendritic
cells. It has 2 ligands, PD-ligand 1 (L1) and PD-ligand 2
(L2). When PD-1 and PD-L1 bind to each other, a
biochemical “shield” is formed, which leads to T-cell
inactivation and protection of the tumor cells from
being destroyed by the immune system. Monoclonal
antibodies directed against PD-1 constitute a class of
drugs that prevent engagement of PD-1 to its li-
gands,108,109 rescuing the activated T-cell from
apoptotic death and thus allowing it to continue its
attack on tumor cells. Nivolumab and pembrolizumab
are 2 monoclonal antibody therapies designed to
directly block the interaction between PD-1 and its
ligands in the treatment of melanoma, lung cancer,
renal cancer, and hematological malignancies, and have
been used since 2014.110 The objective of blocking
program cell death is to restore the activation of theKidney International Reports (2017) 2, 108–123immune system, directed to tumor cells. These agents
are referred to as immune checkpoint inhibitors.108-110
Nivolumab
Nivolumab was the ﬁrst antiPD-1 antibody, tested
initially in melanoma. In December 2014, the FDA
granted an accelerated approval to nivolumab for the
treatment of patients with unresectable or metastatic
melanoma.111 Since then, this agent has also been
approved for use in renal cell cancer.112 In 1 trial,111
there was an increased incidence of elevated creatinine
noted in the nivolumab-treated group as compared to
the chemotherapy-treated group (13% vs. 9%). Steroids
helped to resolve the renal dysfunction in 50% of the
cases. The FDA label113 has guidelines to start steroids if
the creatinine rises rapidly. Recently, there were 4
biopsy-proven cases of acute interstitial nephritis (AIN)
related to nivolumab described in a case series.114 All
patients in this series were also taking other drugs
(proton pump inhibitors, nonsteroidal anti-inﬂammatory
drugs) linked to AIN, but in most cases, the use of these
drugs long preceded antiPD-1 antibody therapy.
Treatment with steroids resolved the AIN in most cases,
and rechallenge with nivolumab in 1 case resulted in
recurrence of AIN. Cortazar et al. reported an additional
case of diffuse AIN with this agent.115 Steroids were
administered, with no response. The authors think that
the PD-1 inhibitor therapy may release suppression of T-
cell immunity that normally permits renal tolerance of
drugs known to be associated with AIN.114,115 The AKI
appears late, usually in the 6- to 12-month period.
Hyponatremia has also been reported with this agent, in
25% of the cases. The underlying mechanism remains
unclear.2,113 In the FAERS analysis,2 we found 20 cases
of AKI, 14 of hyponatremia, and 5 of hypokalemia
associated with nivolumab.
Pembrolizumab
Pembrolizumab (MK-3475) is another monoclonal anti-
body therapy designed to directly block the interaction
between PD-1 and its ligands. This drug has been used
in melanoma and hematological malignancies since
2014. In the initial trials, acute interstitial nephritis was
conﬁrmed by kidney biopsy in 2 of 3 patients with
AKI. All 3 patients fully recovered renal function with
treatment with high-dose corticosteroids ($40 mg
prednisone or equivalent per day) followed by a
corticosteroid taper.116,117 The Keynote-2 study118 re-
ported grade 3 to 4 adverse events that included
generalized edema and myalgia (each in 2 patients
[1%]) in those given pembrolizumab 2 mg/kg, and
hypopituitarism and hyponatremia (each in 2 patients
[1%]) in those given pembrolizumab 10 mg/kg. The117
Table 5. Comparison of renal toxicities of CTLA-4 antagonists and
PD-1 inhibitors2,114,115,121,122,124,126-128
Toxicity
CTLA-4 antagonists
(ipilimumab)
PD-1 inhibitors
(nivolumab and pembrolizumab)
Onset of AIN AIN appears 6–12 weeks
after initiation of therapy
AIN appears 3–12 mo after
initiation of therapy
Glomerular ﬁndings Podocytopathy reported No cases of
podocytopathy reported
Electrolyte disorders Hyponatremia cases
related to hypophysitis
Hyponatremia is rare
AIN, acute interstitial nephritis; CTLA-4, cytotoxic T lymphocyte antigen4; PD-1,
programmed cell death–1.
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biopsy-proven cases of AIN with this agent.114 One
case of rhabdomyolysis and AKI has been reported,119
and renal failure occurred in 2% of the patients in a
recent review.115 Cortazar et al.115 reported 2 additional
cases of AIN, 1 case that presented at 3 weeks and
another at 33 weeks after drug initiation. Both patients
received steroids; 1 patient responded partially and
required dialysis, and the other patient responded with
complete recovery. Overall, the 4 cases of biopsy-
proven AIN reported with this agent were in the
timeframe of 1 month to 12 months. Of the case pa-
tients, 75% responded to steroids with complete
remission, and 1 patient required dialysis and had
partial remission with steroids. The steroids used were
variable, from i.v. forms to oral steroids for a 1- to 3-
month timeframe. Compared to cases reported in the
literature, the FAERS analysis found 19 cases of
hyponatremia and 16 cases of AKI. There were also 4
reports of hypokalemia and hyperkalemia. It is possible
that the electrolyte disorders are related to hypopitu-
itarism. Given the immune-mediated mechanism of
action of this drug, the kidney can be a potential target
and can lead to AIN.
IMMUNE CHECKPOINT INHIBITOR:
CYTOTOXIC T LYMPHOCYTE ANTIGENL4
(CTLA-4) AS A TARGET
Ipilimumab
Ipilimumab is a monoclonal antibody that has antitumor
activity by targeting CTLA-4 and activating the immune
system. This agent is also considered an immune
checkpoint inhibitor. A member of the Ig family, CTLA4
is expressed on CD4þ T-helper cell surface and trans-
mits an inhibitory signal to T cells. Blocking of CTLA-4
prevents this signal and improves antineoplastic
response. Ipilimumab is an antibody that binds to hu-
man CD152 and enhances T-cell response, especially
against tumor cells. Migration of activated T cells into
the kidney leads to AKI. Cell-mediated immune response
leading to inﬂammatory cell inﬁltrates with and without
granulomas have been reported.120,121 At least 12 cases
of AIN in the initial trials, arising 2 to 12 weeks after
drug administration, have been reported, and 1 of them
demonstrated granulomas.115,121–124 The largest series
of 6 cases of AIN was reported by Cortazar et al.115
Pathology revealed AIN in most cases, with varying
degrees of foot process effacement. Cortazar et al.
also reported 1 additional case of thrombotic micro-
angiopathy (TMA) related to ipilumumab.115 In a
phase III study conducted in patients with melanoma
recently,125 no renal toxic effects were reported. Based
on our review of the literature, 2 cases of nephrotic
syndrome126,127 have also been reported, 1 patient with a118lupus-like nephritis with a membranous pattern of
injury126 and the other with minimal change in dis-
ease.127 The electrolyte disorders are not well reported in
the literature with this agent. Two cases of hypona-
tremia have been published.128 A possible cause of
hyponatremia is a syndrome of inappropriate antidi-
uretic hormone from hypophysitis. This complication
related to the agent has now been well reported.129,130 In
the FAERS analysis,2 ipilumimub, with 508 events, had
the highest number of reports of renal events of all
recently used targeted therapies. Most were AKI, fol-
lowed by hyponatremia and hypokalemia. Hypona-
tremia related to this agent should prompt consideration
of a pituitary-related disorder. In summary, ipilimumab
is clearly nephrotoxic, with many cases of AKI and
electrolyte disorders reported in the literature and
FAERs reports. Most of the AKI occurred at 6- to
12-weeks’ time following the start of treatment with this
agent. Steroids remitted most cases of AIN with this
agent. Some patients had partial remission, and a few
required dialysis as well. AKI likely falls under
an immune-mediated mechanism of injury, as noted
with other immune checkpoint inhibitors. Hence, cor-
ticosteroids remain the mainstay of treatment for AIN
related to ipilumumab therapy. In the literature of cases
reviewed, steroids were administered in various form;
some patients received oral prednisone 60 mg daily and
tapered over 3 months, and some received i.v. solume-
drol ranging from 250 mg to 500 mg for 3 to 4 days and
then tapered to oral steroids.
Table 5 compares the renal toxicities of both immune
checkpoint inhibitor classes (CTLA-4 antagonists and
PD-1 inhibitors). For both immune checkpoint inhibitors
(antiPD-1 and CTLA-4), if AKI is conﬁrmed on a kid-
ney biopsy as AIN or a podocytopathy, we would
recommend checkpoint inhibitor discontinuation and a
course of corticosteroids. However, we cannot recom-
mend a deﬁnitive dose and duration of steroid therapy.
Based on cases reported, prednisone 1 mg/kg with a 1- to
2-month taper may be sufﬁcient. We additionally
recommend weekly creatinine monitoring for 1 month
after completing steroids. Rechallenge with immune
checkpoint therapy may be reasonable if otherKidney International Reports (2017) 2, 108–123
Table 6. Recommended routine physical examination, imaging, and
serum and urine monitoring with various targeted therapies
Blood pressure monitoringa
Peripheral edema examinationb
Serum creatinine
Serum potassium
Serum phosphorus
Serum sodium
Serum calcium
Serum magnesiumc
Complete blood count
Urinalysis evaluation for cells and casts
Urine protein/creatinine ratioa
LDHa
Haptoglobina
CKd
Renal sonogram for cyst evaluationb
BCR-ABL, breakpoint cluster region–abelson; CK, creatinine kinase; LDH, lactate
dehydrogenase.
Most targeted therapies require all the tests listed below, and a few require extra tests
that are labeled with the legend below.
aAntivascular endothelial growth factor (VEGF) agents, tyrosine kinase inhibitors,
cytotoxic T lymphocyte antigen4 (CTLA-4) inhibitor.
bCrizitonib.
cEpidermal growth factor (EGFR) inhibitors.
dBCR-ABL tyrosine kinase inhibitors.
KD Jhaveri et al.: Adverse Renal Effects of Oncologic Targeted Therapies REVIEWpotentially offending agents are withdrawn and AIN has
resolved. With this approach, serum creatinine should
be monitored regularly, with reinstitution of steroids at
the ﬁrst sign of AKI from AIN without another cause.
For patients on ipilimumab, renal function monitoring
should be more frequent in the ﬁrst 3 months, as the
injury appears to occur earlier in the treatment course.
For the PD-1 inhibitors, the injury usually happens
later, so monitoring serum chemistries on a monthly
basis might be more prudent.
DOSING OF TARGETED THERAPIES IN CKD
AND DIALYSIS
Because the majority of the targeted therapies are
associated with renal toxicity, dosing in CKD and
patients on dialysis is of great importance. As noted in
prior chemotherapy trials, most trials excluded patients
on dialysis or with severe CKD (GFR < 30). This limits
understanding of dosing in CKD and dialysis. In
Table 1, we summarize the existing published literature
on dosing of these agents in CKD and dialysis (wher-
ever data are available).
CONCLUSIONS
The use of novel targeted therapies has led to signiﬁ-
cant improvement in survival and overall prognosis
with many malignancies. However, there is evolving
knowledge on renal adverse events with these agents.
Timely recognition of these toxicities can aid in the
proper management of cancer patients. In this study
and review, we recognized that there are multiple ways
in which targeted therapies can have an impact onKidney International Reports (2017) 2, 108–123renal function. Table 6 summarizes our recommended
monitoring strategy for patients receiving these agents.
In addition, newer targeted agents are entering clinical
trials. It is exceedingly difﬁcult to keep up with all the
new drugs along with their associated renal toxicities.
Therefore, it is important that the medical community
advocates for an international database registry for
targeted therapies and their renal adverse effects.
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